Growth Investor27 : Had great earnings and rallied to $1.86, sold off with the markets. Buy as much as you can, I take the drug NEXLIZET it works excellent, my #'s are down 49% I have no Side effects, Statin drugs made me feel horrible, muscle pain & no energy, Now I feel GREAT. Best drug out there.

Growth Investor27 : I bought more

Growth Investor27 : My advice buy $ESPR stock, they are same price and ESPR has huge upside reward. average target is $7 by 9 analysts. They will be profitable this year and a strong chance of being acquired, $Pfizer (PFE.US)$ I think would be smart to buy them, possibly $Johnson & Johnson (JNJ.US)$ Esperion sells the only FDA labeled statin alternative for primary prevention. Huge market, Insurance started covering the cost of the prescriptions 5 months ago.

Growth Investor27 : $Esperion Therapeutics (ESPR.US)$ Give it time, Institutions & hedge funds have been accumulating & now own 73% of the outstanding shares, see FINTEL website. Today's news was actually very good, because Esperion is selling the drug at a profit to the Australian pharma company & It will generate immediate cash for Esperion. Daiichi Sankyo Europe will take over the cost of goods this year so that will drop the lower Esperions yearly expense by $50 to $100 million, I read it's $0.30c a pill loss for esperion supplying Daiichi.  Esperion low end prediction for 2025 for U.S sales is $140 million. They have $160 million cash now & they will get $130 million this year from Otsuka and royalties will start. In 2026 Esperion will generate a decent profit. I estimate ESPR will be above $10 a share by this time next year.

Growth Investor27 HH1000 : $Esperion Therapeutics (ESPR.US)$ To the Moon. It has been sold hort & forced lower before an offer comes

Growth Investor27 : makes a lot of sense